Chase Investment Counsel’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Chase Investment Counsel’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-23,869	Closed	-$2.57M	–	146
2021 Q4	$2.57M	Buy	+23,869	New	+$2.6M	1.03%	40
2019 Q1	–	Sell	-17,970	Closed	-$351K	–	112
2018 Q4	$351K	Buy	+17,970	New	+$352K	0.21%	71

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Chase Investment Counsel's HZNP Position: Q1 2022 in Review

Chase Investment Counsel sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2022, closing a stake of 23,869 shares — an estimated $2.57M sold.

Chase Investment Counsel first reported a position in HZNP in Q4 2018 and held it in 2 quarters. The position peaked at $2.57M in Q4 2021. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

Chase Investment Counsel reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2022 after selling out during the quarter.
Chase Investment Counsel sold 23,869 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $2.57M.
Chase Investment Counsel first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 2 quarters.
Chase Investment Counsel's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.57M in Q4 2021.
620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on Chase Investment Counsel's 13F filing for Q1 2022, filed 21 Apr 2022.